One step forward, two steps back for prescription apps
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Strong Zolgensma start bodes ill for Biogen
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
A change of the guard for the world’s biggest cancer companies
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
EADV 2019 – Pfizer carves out a niche for abrocitinib
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Deal-depressed third quarter leaves nowhere to hide
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Esmo 2019 makes for a disappointing read-across to biotech
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.